Currently out of the existing stock ratings of Carl Byrnes, 70 are a BUY (87.5%), 8 are a HOLD (10%), 2 are a SELL (2.5%).

Carl Byrnes

Work Performance Price Targets & Ratings Chart

Analyst Carl Byrnes, currently employed at NORTHLAND CAPITAL MARKETS, carries an average stock price target met ratio of 26.35% that have a potential upside of 26.74% achieved within 224 days. Previously, Carl Byrnes worked at LAKE STREET.

Carl Byrnes’s has documented 152 price targets and ratings displayed on 21 stocks. The coverage is on Healthcare, Consumer Defensive, Energy sectors.

Most recent stock forecast was given on BWAY, Brainsway Ltd at 12-Nov-2025.

Wall Street Analyst Carl Byrnes

Analyst best performing recommendations are on ESPR (ESPERION THERAPEUTICS).
The best stock recommendation documented was for ESPR (ESPERION THERAPEUTICS) at 2/24/2020. The price target of $60 was fulfilled within 1 day with a profit of $2.86 (4.55%) receiving and performance score of 45.5.

Average potential price target upside

of $10.37 (51.48%) on BLFS (BIOLIFE SOLUTIONS).
of $2.71 (41.31%) on BWAY (BRAINSWAY LTD).
of $9.93 (35.63%) on ESPR (ESPERION THERAPEUTICS).

ESPR Esperion Therapeutics FLXN Flexion Therapeutics ADMS Adamas Pharmaceuticals NBRV Nabriva Therapeutics AG PTE Polarityte VTVT vTv Therapeutics ZGNX Zogenix AMRN Amarin PLC ALVO Alvotech ARDS Aridis Pharmaceuticals BLFS BioLife Solutions BWAY Brainsway Ltd MDXG MiMedx Group GWPH GW Pharmaceuticals plc HRTX Heron Therapeuti DRRX Durect ADM Archer-Daniels-Midland Company MDAI Spectral AI NBR Nabors Industries Ltd TLSI TriSalus Life Sciences ZGN Ermenegildo Zegna NV

Show more stocks

Analyst name

Rating

Current price target

Potential Upside

Previous price target

Date of last PT

Price targets met ratio

Average potential upside

Average Days to Hit Target

Performance score

Serge Belanger (NEEDHAM)